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Ari B. Cuperfain, Patrick F. Sullivan, Michael Christiansen, James L. Kennedy, and Lei SunABSTRACT
BACKGROUND: The genetic risk factors of schizophrenia (SCZ), a severe psychiatric disorder, are not yet fully
understood. Multiple lines of evidence suggest that mitochondrial dysfunction may play a role in SCZ, but
comprehensive association studies are lacking. We hypothesized that variants in nuclear-encoded mitochondrial
genes inﬂuence susceptibility to SCZ.
METHODS: We conducted gene-based and gene-set analyses using summary association results from the
Psychiatric Genomics Consortium Schizophrenia Phase 2 (PGC-SCZ2) genome-wide association study comprising
35,476 cases and 46,839 control subjects. We applied the MAGMA method to three sets of nuclear-encoded
mitochondrial genes: oxidative phosphorylation genes, other nuclear-encoded mitochondrial genes, and genes
involved in nucleus-mitochondria crosstalk. Furthermore, we conducted a replication study using the iPSYCH SCZ
sample of 2290 cases and 21,621 control subjects.
RESULTS: In the PGC-SCZ2 sample, 1186 mitochondrial genes were analyzed, among which 159 had p values , .05
and 19 remained signiﬁcant after multiple testing correction. A meta-analysis of 818 genes combining the PGC-SCZ2
and iPSYCH samples resulted in 104 nominally signiﬁcant and nine signiﬁcant genes, suggesting a polygenic model
for the nuclear-encoded mitochondrial genes. Gene-set analysis, however, did not show signiﬁcant results. In an in
silico protein-protein interaction network analysis, 14 mitochondrial genes interacted directly with 158 SCZ risk genes
identiﬁed in PGC-SCZ2 (permutation p = .02), and aldosterone signaling in epithelial cells and mitochondrial
dysfunction pathways appeared to be overrepresented in this network of mitochondrial and SCZ risk genes.
CONCLUSIONS: This study provides evidence that speciﬁc aspects of mitochondrial function may play a role in SCZ,
but we did not observe its broad involvement even using a large sample.
Keywords: Gene-gene interaction, GWAS-HD, MAGMA, Mitochondria, Oxidative phosphorylation, Schizophrenia,
Stratiﬁed FDR
https://doi.org/10.1016/j.biopsych.2018.02.1175Schizophrenia (SCZ) is a severe psychiatric disorder for which
the underlying causes are far from fully understood. The brain
is highly dependent on oxidative metabolism as the primary
source of energy to maintain its functions (1), and a distur-
bance in brain energy metabolism has been suggested as part
of the pathogenesis of SCZ (2). Studies have indicated that
abnormalities in glucose oxidative metabolism may contribute
to an individual’s susceptibility of developing psychosis (1,3).
Indeed, there is compelling evidence that patients with SCZ
have impaired glucose metabolism, with decreased metabolic
rates and reduced blood ﬂow in the frontal cortex exhibited
during cognitive tasks (4–7).
Impaired oxidative metabolism suggests mitochondrial
dysfunction mainly because these organelles are the primary
sources of aerobic energy via oxidative phosphorylation
(OXPHOS) for neuronal function. Furthermore, it has been
shown that mitochondria play an important role in cellular
processes that are disturbed in SCZ, such as synapticª 2018 Society of Biological Psychiatry. This is an open access ar
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc
ical Psychiatry May 1, 2018; 83:780–789 www.sobp.org/journaltransmission (8–10) and oxidative stress (11). Comorbidity
between mitochondrial diseases and neuropsychiatric symp-
tomatology has also been reported (12,13).
SCZ has a strong genetic basis, with estimated heritability
around 80% (14). However, few studies aim speciﬁcally to
discover mitochondrial loci associated with SCZ, and conse-
quently, genetic data supporting the association of mito-
chondrial loci with SCZ are lacking. There is some evidence
that mitochondrial genes play a role in SCZ [for a review, see
Hjelm et al. (9)]. For example, the most recent results from the
Psychiatric Genomics Consortium Schizophrenia Phase 2
(PGC-SCZ2) genome-wide association study (GWAS) (35,476
cases and 46,839 control subjects), the largest dataset to date
used for genetic association studies of SCZ, reported evidence
for 22 nuclear-encoded mitochondrial genes (15), but
mitochondria-related pathways showed no signiﬁcant associ-
ation with the disease in another large study of SCZ (9379
cases and 7736 control subjects) (16). Further evidenceticle under the
-nd/4.0/).
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and an excess of large (.500 Kb) deletions, and rare copy
number variants in nuclear-encoded mitochondrial genes in
individuals with SCZ (18).
Here we tested the hypothesis that variants in nuclear-
encoded mitochondrial genes inﬂuence SCZ risk. Because
mitochondrial genes have unique features (being encoded by
both the nuclear and mitochondrial genomes) and contain
highly connected signaling pathways (for maintenance of
mitochondria homeostasis), we performed both gene-based
and gene-set/pathway analyses.
Of particular interest is the set of nuclear-encoded OXPHOS
genes, the mitochondrial pathway that produces adenosine
triphosphate (ATP) for neuronal functioning. This speciﬁc
pathway has been more intensively investigated in SCZ, mainly
due to the critical role of mitochondrial reactive oxygen species
in triggering oxidative stress. SCZ patients have been reported
to show increased levels of oxidative stress (2), and the SCZ-
oxidative stress association has been noted in functional
studies (19). Moreover, there is compelling evidence linking
reactive oxygen species with immune-inﬂammatory pathways
(20,21), which have also been implicated in SCZ (22,23).
Speciﬁc nuclear-encoded OXPHOS genes physically
interact with other subunits encoded by the mitochondrial
DNA. Therefore, the mitochondria and nucleus must coordi-
nate transcription, translation, import, and function of mito-
chondrial protein complexes (24). Disturbances in this
crosstalk may lead to deﬁciencies in the mitochondrial ATP
production process, causing or contributing to disease.
We deﬁned three sets of genes to test our hypothesis that
variants in mitochondrial or mitochondria-related genes inﬂu-
ence SCZ risk: 1) nuclear-encoded OXPHOS genes, 2) other
nuclear-encoded mitochondrial genes (excluding the OXPHOS
genes), and 3) genes involved in the crosstalk between the
nucleus and mitochondria (25). Using the MAGMA tool (26)
alongside a hypothesis-driven GWAS (GWAS-HD) approach
(27), we aimed to 1) identify and replicate new mitochondrial
susceptibility loci for SCZ, 2) evaluate the signiﬁcance of the
three mitochondrial gene sets in SCZ, and 3) use in silico tools
to predict the biological processes involving mitochondrial
genes identiﬁed in this study, to potentially reveal novel
abnormal cellular circuits in SCZ.
METHODS AND MATERIALS
Samples
We used the summary association statistics available from the
most recent PGC-SCZ2 GWAS (15) to perform our analyses in
the discovery sample. The original quality control steps for
35,476 SCZ cases and 46,839 control subjects from 52
cohorts, and detailed association analyses of 9,444,230
single nucleotide polymorphisms (SNPs) are described else-
where (15).
To replicate ﬁndings, we used the iPSYCH GWAS data
(www.ipsych.au.dk) with 2290 SCZ cases and 21,621 control
subjects. Subjects were genotyped using the Illumina Inﬁnium
PsychChip v1.0 (Illumina, Inc., San Diego, CA) in accordance
with the manufacturer’s instructions. The total number of
genotyped SNPs was 588,454 (28). Preimputation quality
control steps included removal of SNPs with minor alleleBiologicafrequency ,0.05 and Hardy-Weinberg equilibrium p , 1026 in
control subjects, and removal of individuals with call rate
,95% and (cryptic) ﬁrst- and second-degree relatives using
KING (v1.9) (29). The data were then phased using Shapeit3
(v2.r837) (30) and imputed using IMPUTE2 (v2.3.2) (31), with
the 1000 Genomes Project Phase 3 as the reference panel.
Postimputation quality control included removal of SNPs with
INFO score ,0.2, minor allele frequency ,0.001, genotype
missing rate .10%, and Hardy-Weinberg equilibrium p ,
1026, resulting in a total of 8,842,045 SNPs for analysis.
Nuclear-Encoded Mitochondrial Genes and
Mitochondria-Related Gene Sets
The OXPHOS gene set started with 95 nuclear-encoded genes
selected using KEGG (32). All 95 were listed in the MitoCarta
2.0 release 2015 (33), a database of human genes with strong
evidence for mitochondrial location based on computational
and microscopy evidence. In total, 89 genes tagged by 6686
PGC-SCZ2 GWAS SNPs formed the OXPHOS gene set.
The mitochondrial gene set originally included 1158
nuclear-encoded genes downloaded from MitoCarta. Two
genes encoded in the extended major histocompatibility
complex (34) were excluded; the major histocompatibility
complex region is known to be highly associated with SCZ and
was thus excluded for a conservative analysis. After removal of
these genes, 1038 genes tagged by 131,502 SNPs remained,
and they formed the mitochondrial gene set (excluding the
OXPHOS genes deﬁned by the gene set above).
The nucleus-mitochondria crosstalk gene set included 76
genes selected based on previous literature (24,35–37). These
genes were tagged by 18,781 SNPs. One gene also appeared
in the OXPHOS group, and 16 genes appeared in the mito-
chondrial group. We decided to keep these overlapping genes
in both groups because they may be part of several different
cellular processes/circuits involving mitochondria.
In total, 155,843 unique SNPs were located within the
genomic region of 1186 unique mitochondrial or mitochondria-
related genes; only SNPs within transcribed regions were
included to minimize overlapping of SNPs between multiple
genes and inclusion of null SNPs (38).
MAGMA Gene-Based and Gene Set Analyses
The PGC-SCZ2 GWAS p values (after the genomic control [GC]
adjustment) were the primary input data for MAGMA (v1.06) with
the 1000 Genomes Project Phase 3 (Build 37/European data
only) used as the reference panel. We calculated the linkage
disequilibrium score intercept for the PGC-SCZ2 GWAS data
and found a value of 1.052, suggesting a slight inﬂation even
after correction for thepolygenicnatureofSCZ.Thus,weapplied
the conservative GC correction to the original SNP association
results before conducting our analyses, ensuring that the
remaining enrichment was genuinely due to a polygenic model.
The MAGMA gene-based results (using the SNP-wise op-
tion) were then corrected for multiple testing of the 1186
mitochondrial genes using the Bonferroni method. MAGMA
gene-set competitive analysis [with default parameter values
and correcting for potential confounders and linkage disequi-
librium score between genes (26)] was then performed to
examine if any of the three mitochondrial gene sets wasl Psychiatry May 1, 2018; 83:780–789 www.sobp.org/journal 781
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tested).
Hypothesis-Driven GWAS
Given that the MAGMA method only analyzed the deﬁned
genes and gene sets, we used the GWAS-HD and stratiﬁed
false discovery rate (sFDR) (27) to complement the MAGMA
analysis. GWAS-HD re-evaluates (upweight or downweight
through the sFDR control) all individual SNP associations
genome wide, based on the prior information contained in the
biological hypothesis. SNPs annotated to the three mito-
chondrial gene sets were assigned to three high-priority strata,
and the remaining SNPs formed a separate (low priority) stra-
tum. We emphasize here that SNP stratiﬁcation must be done
a priori independent of the p values to be stratiﬁed. The sFDR
method improves power if the prior information is informative;
the high-priority group(s) indeed contains proportionally more
truly associated SNPs as compared with no stratiﬁcation (39).
Replication Study
To replicate associationbetween individual SNPsandSCZ, a list
of 657 SNPs (with sFDR q value, .05) were sent to the iPSYCH
Mitochondria Group investigators in Denmark. The same
MAGMA approach used in the discovery PGC-SCZ2 sample
was applied to the iPSYCH SCZ sample to replicate the gene-
based ﬁndings. A meta-analysis using Fisher’s method to
combine the discovery and replication gene-basedp valueswas
performed. Genes with p values less than the conservative
Bonferroni correction threshold were declared signiﬁcant.
Mitochondrial Gene Expression in the Brain
We used the Allen Human Brain Atlas to explore the expres-
sion of the associated genes across human brain regions to
look for additional evidence of their potential role in SCZ.
Microarray data for 6 subjects (4 men and 2 women 18 to 68
years of age with no known neuropsychiatric or neuropatho-
logical history) were downloaded from Allen Human Brain Atlas
(http://human.brain-map.org/static/download) in July 2017.
The Atlas used a custom design Agilent 8x60K array that
included the 4x44K Agilent Whole Human Genome probe set
supplemented with an additional 16,000 probes. As probes for
the same gene were highly correlated, only one probe per gene
was selected to avoid collinearity. This probe selection was
based on expression levels, with moderate expression levels
deﬁned conservatively as .6; the median expression for all
genes across the brain for the 6 subjects was 4.99 and the
75th quartile was 7.13.
Differential Expression of Genes in SCZ
The .bam ﬁles were obtained through the CommonMind
Consortium Knowledge Portal (https://www.synapse.org/
CMC) (the largest RNA sequencing dataset for human dorso-
lateral prefrontal cortex) with permission and analyzed at Uni-
versity of California, Irvine (40). Data from 10 duplicate samples
and 89 individuals with incomplete demographic information
were excluded. The analysis included 514 samples and the
following factors were used to correct for differences between
brain samples: pH, age, postmortem interval, RNA integrity
index, batch, institution, and the manner of death.782 Biological Psychiatry May 1, 2018; 83:780–789 www.sobp.org/jouThe linear regression model included the following terms in
R package (glm) (R Project for Statistical Computing, Vienna,
Austria): Gene Expression (log counts per million) = b0 1 b13
(diagnosis) 1 b2 3 (brain pH) 1 b3 3 (postmortem interval) 1
b4 3 (age) 1 b5 3 (sex) 1 b6 3 (RIN) 1 b7 3 (institution) 1
b8 3 (cause of death) 1 ) 1 ε.
Log counts per million values were obtained from RNA
sequencing read counts divided by the corresponding library
size (in millions) to yields counts per million (41). Postmortem
interval is in hours, RNA integrity number was obtained from
Agilent BioAnalyzer, and institution was coded for each of
three sites (Icahn School of Medicine at Mount Sinai, University
of Pittsburgh, University of Pennsylvania).Gene-Gene Interaction and Overrepresentation
Analyses
Genes that belong to the same molecular networks and
cellular pathways are often involved in the pathophysiology of
the same or similar conditions (41). Therefore, we mapped
functionally relevant physical interactions using an in silico
protein-protein interaction (PPI) network analysis. We tested
gene–gene interactions among genes that code for interacting
proteins, particularly the 19 nuclear-encoded mitochondrial
genes signiﬁcantly associated with SCZ in the discovery
sample using a gene-based approach, as well as the 327
genes in the 108 genome-wide signiﬁcant loci reported in the
original PGC-SCZ2 study (15).
We ﬁrst built a PPI network with the 327 SCZ risk genes (of
which 10 were not recognized by the program for encoding
microRNAs) to visualize how these genes interact among each
other in a functional network using GeneMANIA Cytoscape
Plugin (Cytoscape_v3.5.1) (42). These initial 327 genes were
referred as seed genes. To visualize and analyze topological
parameters of the network, we used the Cytoscape platform
(43) and the CentiScape plugin (44). After constructing the
network, we then used GeneNets toolbox in MATLAB (R2015a;
The MathWorks, Inc., Natick, MA) (45) to determine whether
the connectivity among the 327 seed genes was statistically
signiﬁcant compared with a randomly selected network of
similar size (taking into account number of genes and genes
sizes).
We then used GeneNets to investigate whether this network
formed by 327 seed genes (the SCZ risk genes) signiﬁcantly
connect with the backbone genes (i.e., mitochondrial genes
considered signiﬁcant in this study), using the default seed
randomization option. We called the network built from
this analysis the mito-SCZ network. Mitochondrial and SCZ
genes physically interacting in the mito-SCZ network were
selected for gene-set overrepresentation analysis in the
GeNets software (Broad Institute of MIT and Harvard,
Cambridge, MA).
GeNets is a web platform (http://apps.broadinstitute.org/
genets) for analysis and interpretation of genetic variation in
the context of gene-gene networks (46). GeNets allowed us to
visualize genes that interact with each other as well as their
communities (i.e., a group of genes relatively more connected
with each other in a network), while taking into account the
biological process related to the genes. Additional candidate
genes could be predicted as well. This software investigatesrnal
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using a Bonferroni-adjusted hypergeometric test. In our study,
only gene sets from the Molecular Signatures Database were
used.
GeNets also includes Quack (https://www.biorxiv.org/
content/biorxiv/early/2017/10/04/196303.full.pdf), a machine
learning algorithm that can be trained to ﬁnd nontrivial pathway
relationships between genes of interest. The hypothesis is that
genes in a common pathway would share pathway-speciﬁc to-
pological properties (connectivity proﬁles) that systematically
distinguish them from genes that are not part of the pathway
under analysis. The algorithm generates a conﬁdence score
(from0 to 1) that ranks each gene; geneswith higher scores have
greater probability being related to the pathway under analysis.
Last, we used Ingenuity Pathway Analysis software
(v33559992, release date March 28, 2017; QIAGEN Bioinfor-
matics, Redwood City, CA) with default parameter values to
determine whether the genes in the mito-SCZ network were
enriched for speciﬁc biological pathways. The p values were
adjusted using the default option, i.e., the FDR-adjusted p
(Benjamini-Hochberg method) (47). We used the lenient FDR
control to identify as many candidate pathways as possible
while still maintaining an acceptable false positive rate.
RESULTS
Gene-Based and Gene-Set Analysis
We used MAGMA to conduct gene-based analysis of the
1186 OXPHOS, mitochondrial, and nucleus-mitochondria
crosstalk genes using PGC-SCZ2 as our discovery sample.
In total, 159 mitochondrial genes had MAGMA gene-basedTable 1. Mitochondrial Genes Signiﬁcantly Associated With SCZ
Correction for 1186 Multiple Hypothesis Tests
Symbol CHR Start Stop
No. of SNPs
Annotated
APOPT1 14 104029299 104057236 59
C12orf65 12 123717844 123742651 68
HSPE1-MOB4 2 198364721 198418423 63
C2orf69 2 200775979 200792996 43
C2orf47 2 200820040 200828848 19
PCCB 3 135969167 136056737 148
ATPAF2 17 17921334 17942483 25
HSPA9 5 137890571 137911318 37
DNAJA3 16 4475806 4506776 71
NT5DC2 3 52558385 52569093 26
LETM2 8 38240041 38267045 36
NDUFA6 22 42481530 42486888 9
HSPD1 2 198351308 198364998 18
DNAJC19 3 180701497 180707562 4
COQ10B 2 198318231 198339851 20
SMDT1 22 42475695 42480288 5
FOXO3 6 108881026 109005972 171
HSPE1 2 198364721 198368187 2
ABCB9 12 123405498 123451056 42
CHR, chromosome; SCZ, schizophrenia; SNPs, single nucleotide polym
ap values after the conservative Bonferroni correction.
Biologicap , .05, 19 of which survived Bonferroni correction
(Table 1). In total, 818 mitochondrial genes had data in both
the PGC-SCZ2 discovery and iPSYCH replication samples,
and meta-analysis resulted in 104 genes with gene-based p
, .05 and nine with p , .05/818 (Bonferroni correction)
(Table 2). Notably, among 1000 randomly selected sets of
818 genes from the nuclear genome, the numbers of gene-
based p , .05 ranged from 66 to 123, with a mean of
92.15 (ﬁrst quartile of 84, median of 92.5, and third quartile of
98). Among the total of 1000 replicates, there were 46 repli-
cates with counts $104 (the value observed in the set of
nuclear encoded mitochondrial genes), resulting in an
empirical p = .046 for the enrichment analysis of truly asso-
ciated genes. This ﬁnding suggests that the polygenic model
known for the nuclear genome appears to hold for the set of
nuclear-encoded mitochondrial genes analyzed. Furthermore,
q-q plots, expressed on a –log10(p) scale in Figure 1, show
evidence for enrichment, with an estimated proportion of
associated genes of 3%, 8%, and 13% for the discovery,
replication, and combined samples, respectively. These esti-
mates are subject to sampling variation (48). We also note
that the q-q plot for a set of p values with a higher estimated
proportion of truly associated variants (e.g., Figure 1B for the
replication sample) could look more “ﬂat” than Figure 1A for
the discovery sample, if the corresponding statistical effect
sizes (which depends on both genetic effect size of a variant
and the sample size) differ.
With respect to gene-set analysis, none of the three sets of
genes showed statistically signiﬁcant enrichment of associa-
tion based on MAGMA, with gene-set p values equal to .40,
.64, and .19 for the OXPHOS, mitochondrial excludingRisk at the p , .05 Level After the Conservative Bonferroni
No. of Relevant
Parameters Used
in the Model n ZSTAT p Value Correct_pa
17 82,315 5.9449 1.38E-09 .000002
11 82,315 5.8275 2.81E-09 .000003
16 82,315 5.5313 1.59E-08 .000019
13 82,315 5.5011 1.89E-08 .000022
10 82,315 4.8352 6.65E-07 .0008
43 82,315 4.8174 7.27E-07 .0009
11 82,315 4.7175 1.19E-06 .0014
16 82,315 4.5898 2.22E-06 .0026
29 82,315 4.3822 5.87E-06 .0070
8 82,315 4.34 7.12E-06 .0084
13 82,315 4.3314 7.41E-06 .0088
5 82,315 4.3137 8.03E-06 .0095
7 82,315 4.2994 8.56E-06 .01
4 82,315 4.267 9.91E-06 .01
6 82,315 4.1766 1.48E-05 .02
3 82,315 4.1677 1.54E-05 .02
32 82,315 4.1328 1.79E-05 .02
2 82,315 4.0746 2.3E-05 .03
18 82,315 4.0223 2.88E-05 .03
orphisms; ZSTAT, Z value for the gene.
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Table 2. List of Nine Mitochondrial Genes Signiﬁcantly Associated With SCZ Risk Through Meta-analysis at the p, .05 Level
After the Conservative Bonferroni Correction for 818 Multiple Hypothesis Tests
Symbol CHR Start Stop
Discovery Replication Meta-analysis
n ZSTAT disc_p n ZSTAT rep_p Fisher_Combined_p Correct_pa
HSPE1-MOB4 2 198364721 198418423 82,315 5.5313 1.59E-08 23,911 20.683 .7527 2.30E-07 .0002
C2orf47 2 200820040 200828848 82,315 4.8352 6.65E-07 23,911 0.55423 .2897 3.17E-06 .0026
SMDT1 22 42475695 42480288 82,315 4.1677 1.54E-05 23,911 2.0424 .0206 5.05E-06 .0041
ATPAF2 17 17921334 17942483 82,315 4.7175 1.19E-06 23,911 0.49159 .3115 5.88E-06 .0048
PCCB 3 135969167 136056737 82,315 4.8174 7.27E-07 23,911 21.4194 .9221 1.02E-05 .0083
NDUFA6 22 42481530 42486888 82,315 4.3137 8.03E-06 23,911 1.2234 .1106 1.33E-05 .0108
HSPA9 5 137890571 137911318 82,315 4.5898 2.22E-06 23,911 20.24631 .5973 1.93E-05 .0158
DNAJA3 16 4475806 4506776 82,315 4.3822 5.87E-06 23,911 0.35949 .3596 2.97E-05 .0243
FOXO3 6 108881026 109005972 82,315 4.1328 1.79E-05 23,911 0.69366 .2440 5.83E-05 .0477
CHR, chromosome code; disc, discovery sample; rep, replication sample; SCZ, schizophrenia; ZSTAT, Z value for the gene.
ap values after the conservative Bonferroni correction.
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respectively. This result could be a true negative, although
genetic heterogeneity may also drive these nonsigniﬁcant
ﬁndings.
GWAS-HD Analysis
In total, summary statistics of 9,444,230 PGC-SCZ2 GWAS
SNPs were available, among which 155,843 unique SNPs were
located within the genomic region of 1186 mitochondrial genes
as deﬁned above. GC-corrected p values were then used for
the GWAS-HD analysis. Speciﬁcally, FDR control was simul-
taneously applied to the four strata of SNPs: stratum 1, con-
taining 6686 OXPHOS SNPs; stratum 2, containing 131,502
mitochondrial SNPs; stratum 3, containing 18,781 nucleus-
mitochondria crosstalk SNPs (1126 overlap with stratum 2);
and stratum 4, containing the remaining 9,239,959 GWAS
SNPs, excluding the major histocompatibility complex region
as discussed before.
In total, 728 mitochondrial SNPs had an sFDR q value, .05,
including 86 SNPs previously reported as genome-wide0.0 0.5 1.0 1.5 2.0 2.5 3.0
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Figure 1. The q-q plot for the (A) discovery, (B) replication, (C) and combined
genes (p) is shown. Exp, expected; Obs, observed.
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GWAS-HD signiﬁcant SNPs mapped to 54 genes, of which all
had MAGMA gene-based p , .05, including the 19 genes
declared signiﬁcant in the PGC-SCZ2 discovery sample using
our approach.
Of the 728 mitochondrial SNPs, 657 with rs numbers
(indels variants excluded) were used for replication analysis
using the independent iPSYCH SCZ sample. In total, 40
SNPs had meta-analysis p value , .05, 35 of which
demonstrated an effect in the same direction as in the PGC-
SCZ2 discovery sample (Table 3). These 35 SNPs were
located within ﬁve genes (APOPT1, NDUFA6, SMDT1, MSRA,
and CAMKK2), all of which showed at least nominally sig-
niﬁcant MAGMA gene-based association with SCZ in our
discovery sample.
Mitochondrial Gene Expression in the Brain
All 19 mitochondrial genes associated with SCZ in this study
were expressed at signiﬁcant levels in human brain tissue
(Supplemental Figure S1), and 17 showed particularly high.5 2.0 2.5 3.0
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rnal
Table 3. List of 35 SNPs Replicated in the iPSYCH SCZ Sample
SNP CHR POS A1 A2
Discovery Replication Meta-analysis
n OR SE p Value n OR SE p Value meta_P corrected_meta_P
rs10431750 14 104040065 T C 82,315 2 0.0115 2.11E-09 23,371 2 0.03401 .03 2.67E-10 9.35E-09
rs1063843 12 121681687 T C 82,315 1 0.0131 4.37E-04 23,911 1 0.03833 .02 2.26E-05 7.92E-04
rs12887734 14 104046834 T G 82,315 1 0.0117 7.03E-10 23,229 1 0.03413 .03 1.06E-10 3.70E-09
rs12889403 14 104034746 T C 82,315 1 0.0116 7.06E-09 23,562 1 0.034 .04 1.25E-09 4.38E-08
rs12889721 14 104034863 T C 82,315 1 0.0116 9.54E-09 23,575 1 0.03399 .05 2.06E-09 7.20E-08
rs12890820 14 104034849 T C 82,315 2 0.0116 5.71E-09 23,584 2 0.03399 .05 1.19E-09 4.17E-08
rs12894729 14 104035292 A G 82,315 1 0.0116 8.18E-09 23,556 1 0.03401 .04 1.47E-09 5.13E-08
rs1653591 12 121681138 A G 82,315 1 0.0131 1.69E-04 23,840 1 0.03844 .02 9.59E-06 3.35E-04
rs2071711 22 42477650 C G 82,315 2 0.0114 3.55E-05 23,842 2 0.03409 .02 1.92E-06 6.72E-05
rs2269524 22 42475703 T G 82,315 1 0.0113 2.75E-05 23,845 1 0.03404 .02 1.61E-06 5.64E-05
rs2274267 14 104029449 A G 82,315 1 0.0117 1.14E-08 23,418 1 0.03404 .03 1.35E-09 4.71E-08
rs2296482 14 104029819 T G 82,315 2 0.0116 7.01E-09 23,708 - 0.03387 .02 6.78E-10 2.37E-08
rs2403197 14 104053764 T C 82,315 1 0.0115 1.89E-09 23,205 1 0.03424 .05 4.27E-10 1.49E-08
rs2668247 12 121684176 C G 82,315 2 0.0131 1.69E-04 23,819 2 0.03848 .02 1.02E-05 3.57E-04
rs2686340 12 121682051 T C 82,315 1 0.0131 1.81E-04 23,742 1 0.03855 .02 9.45E-06 3.31E-04
rs2686342 12 121685188 A T 82,315 2 0.0131 2.17E-04 23,785 2 0.03846 .02 1.34E-05 4.70E-04
rs2686344 12 121690548 T C 82,315 1 0.0125 4.96E-04 22,506 1 0.03729 .02 2.95E-05 1.03E-03
rs2686345 12 121690555 T C 82,315 1 0.0125 5.01E-04 22,506 1 0.03729 .02 2.99E-05 1.04E-03
rs34026011 14 104050883 A G 82,315 1 0.0115 1.12E-09 23,205 1 0.03418 .03 1.90E-10 6.66E-09
rs35026580 14 104042753 A G 82,315 2 0.0115 1.96E-09 23,316 2 0.03405 .02 1.93E-10 6.74E-09
rs35229468 14 104052057 T C 82,315 1 0.0115 1.97E-09 23,212 1 0.03421 .04 3.45E-10 1.21E-08
rs35496194 14 104031351 T C 82,315 1 0.0117 2.66E-09 23,651 1 0.03395 .04 5.42E-10 1.90E-08
rs4147640 22 42485292 T C 82,315 1 0.0113 1.94E-05 23,850 1 0.03405 .02 1.23E-06 4.29E-05
rs4147641 22 42482502 C G 82,315 1 0.0113 2.43E-05 23,846 1 0.03405 .02 1.56E-06 5.47E-05
rs4906336 14 104033265 C G 82,315 2 0.0116 5.17E-09 23,558 2 0.034 .05 1.13E-09 3.94E-08
rs4906337 14 104040414 A C 82,315 1 0.0115 2.12E-09 23,349 1 0.03403 .02 2.13E-10 7.47E-09
rs4906338 14 104050357 A G 82,315 2 0.0115 1.25E-09 23,173 2 0.03419 .03 1.90E-10 6.66E-09
rs58033365 14 104030901 T C 82,315 2 0.0116 6.50E-09 23,711 2 0.03389 .03 8.01E-10 2.80E-08
rs6002592 22 42476754 A C 82,315 1 0.0113 3.46E-05 23,844 1 0.03404 .02 2.04E-06 7.13E-05
rs6002596 22 42484466 A G 82,315 2 0.0114 1.36E-05 23,846 - 0.03406 .02 8.94E-07 3.13E-05
rs7140568 14 104041374 T C 82,315 1 0.0115 2.12E-09 23,335 1 0.03404 .02 1.97E-10 6.88E-09
rs71417868 14 104046592 A T 82,315 2 0.0115 1.32E-09 23,237 2 0.03411 .03 1.83E-10 6.40E-09
rs73191548 8 10035997 A G 82,315 1 0.0109 6.21E-05 23,451 1 0.03213 .04 6.73E-06 2.36E-04
rs8017628 14 104047428 T C 82,315 1 0.0115 1.44E-09 23,233 1 0.03413 .03 2.24E-10 7.85E-09
rs8017993 14 104047734 A G 82,315 2 0.0115 1.69E-09 23,217 2 0.03417 .03 2.78E-10 9.73E-09
A1, allele 1; A2, allele 2; CHR, chromosome code; OR, odds ratio; POS, chromosome location; SCZ, schizophrenia; SE, standard error;
SNP, single nucleotide polymorphism.
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Psychiatrylevels of expression in the thalamic, midbrain, and striatal
areas. Importantly, these brain regions are known to be altered
in SCZ (50). For 17 of these 19 genes, we observed moderate-
to-high levels of log2 expression (log2 score .6) across the
human brain (Supplemental Table S2). The two other genes
had moderate to high expression levels in speciﬁc areas such
as the frontal lobe for ABCB9 or the cerebellar cortex for
LETM2.
Differential Gene Expression of Replicated Genes in
SCZ
Of the nine replicated genes shown in Table 2, three were
downregulated in a nominally signiﬁcant manner in SCZ
compared with control subjects (Table 4).BiologicaPPI Network and Gene Set Overrepresentation
Analysis
The PPI analysis of the 337 SCZ risk genes showed a con-
nected network including 327 seed genes and 5790 in-
teractions (edges in Supplemental Figure S2) between them.
The randomization method showed that the connectivity
among 327 genes was statistically signiﬁcant (p = .034, 1000
randomizations). The greatest number of interactions between
genes in the network was found for those with coexpression,
(i.e., two genes showing similar expression levels in the Gene
Expression Omnibus database, suggestive of coexpression)
(Supplemental Figure S2).
In examining the interaction between the 19 mitochondrial
genes (backbone genes) with the 327 SCZ risk genesl Psychiatry May 1, 2018; 83:780–789 www.sobp.org/journal 785
Table 4. Fold Change of Replicated Mitochondria Genes in
the Dorsolateral Prefrontal Cortex From the CommonMind
Consortium
Symbol
Average
Expression
(CPM) t
p
Value
Fold Change
(Schizophrenia/Control
Subjects) FDRa
NDUFA6 5.91 22.13 .03 21.21 0.25
PCCB 5.78 22.73 .01 21.19 0.14
SMDT1 4.28 22.86 .00 21.23 0.12
Three mitochondria genes shown in Table 2 were nominally
signiﬁcantly decreased in the expression for schizophrenia compared
with control subjects for the CommonMind Consortium dorsolateral
prefrontal cortex after correction for brain pH, age, postmortem
interval, RNA integrity number, batch, institution, and the manner of
death.
CPM, counts per million; FDR, false discovery rate.
aBenjamini-Hochberg–adjusted p value.
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Psychiatry(seed genes), we observed that 14 mitochondrial genes were
connected with 158 SCZ genes in a signiﬁcant network after
the randomization test (p = .023, 1000 randomizations)
(Figure 2 and Supplemental Figure S3). The genes DNAJC19,
HSPA9, PCCB, and HSPE1 showed the greatest number of
connections among mitochondrial genes, interacting with
many genes of the SCZ network.
For the GeNets analysis of functional connectivity among
the 14 mitochondrial genes and 158 SCZ genes, 70 additional
candidates were included to the network, based on their
connectivity with our input genes (selected by the software). Of
the 242 genes examined, 138 genes were connected in a
signiﬁcant network (p = .002), of which 18 were mitochondrial.
Moreover, mitochondrial genes comprised one of the largest
communities in the network (Community 7; Supplemental
Figure S4). For this community, two signiﬁcant canonical159 
nominally 
significant   
genes
Ripke et al., Nature, 2014
337 SCZ 
risk genes
Mito-SCZ 
Network
14158
A
B
C
19327
SCZ network
(327 genes)
D GeNets IPA
786 Biological Psychiatry May 1, 2018; 83:780–789 www.sobp.org/joupathways were overrepresented: 1) respiratory electron trans-
port and 2) ATP synthesis. Furthermore, the gene NDUFA6
from our study was one of the genes included in this com-
munity (Supplemental Table S4). Additionally, GeNets classi-
ﬁed the mitochondrial genes DRG2, NDUFA2, NDUFA6, and
NDUFA13 as the most important genes for the network based
on Quack (Supplemental Table S5).
Finally, the Ingenuity Pathway Analysis of the 14 mito-
chondrial genes and the 158 SCZ genes (mito-SCZ network)
found canonical biological pathways related to mitochondrial
function as overrepresented in this network (after FDR
correction). Particularly, mitochondrial dysfunction and aldo-
sterone signaling in epithelial cells were most overrepresented
(Supplemental Table S6).
DISCUSSION
Regions of the genome robustly associated with schizophrenia
by the PGC-SCZ2 GWAS provide a framework for secondary
analysis to identify important biological pathways and help to
shed further light on disease etiology. Although there were 22
mitochondrial genes among the top PGC-SCZ2 GWAS hits,
the mitochondrial system is not yet widely considered as a
pathophysiologic mechanism in SCZ. To the best of our
knowledge, the study presented here is the ﬁrst to examine
explicitly the role of mitochondria-related genes in SCZ.
Using MAGMA gene-based analysis, we identiﬁed 19
mitochondrial or mitochondria-related genes signiﬁcantly
associated with SCZ at gene level, all of which were corrob-
orated in a separate GWAS-HD sFDR analysis. Of the 19 sig-
niﬁcant genes identiﬁed in the PGC-SCZ2 sample, 12 were
from the mitochondrial gene set, ﬁve were from the nucleus-
mitochondria-crosstalk gene set, and two were from the
OXPHOS gene set. We note that the signiﬁcance here isThis study 
1,186 mito
genes
Figure 2. Protein-protein interaction analysis
workﬂow. (A) Protein-protein interaction analysis of
337 schizophrenia (SCZ) risk genes (15) showed a
signiﬁcant connected network including 327 of these
genes (p = .03). (B) These 327 genes were further
investigated using GeneNets and found to be con-
nected in a network with signiﬁcant mitochondrial
genes from our study (n = 19). (C) A total of 158 SCZ
risk genes were connected with 14 mitochondrial
genes in a signiﬁcant network (p = .02) (mito-SCZ
network). (D) Pathways and biological processes
associated with the mito-SCZ network were inves-
tigated using GeNets and Ingenuity Pathway Anal-
ysis (IPA) software.
rnal
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Psychiatrydeﬁned based on Bonferroni correction for the 1186 genes
tested using MAGMA. However, eight genes overlapped with
those declared as genome-wide signiﬁcant loci by the PGC-
SCZ2 GWAS; the remaining 11 novel genes only passed the
less conservative threshold as deﬁned here. We did not include
regulatory regions in our gene-based analysis and it remains to
be explored further in the future.
Meta-analysis of 818 genes with data in both the PGC-
SCZ2 (discovery) and iPSYCH (replication) samples identiﬁed
104 genes with meta-analysis p , .05, and nine were signiﬁ-
cant after Bonferroni correction for multiple testing.
The q-q plots of gene-based p values in Figure 1 were
suggestive of enrichment of variants associated with SCZ. This
is supported by the stratiﬁed q-q plots of SNP-based p values
in Supplementary Figure S5 where the estimated proportion of
associated SNPs was 3% for the mitochondrial gene set (GC
l = 1.04), and 4% for the nucleus-mitochondria crosstalk gene
set (l = 1.10), as compared with 0.01% for the protein-coding
control group (l = 0.99). The SNPs in the OXPHOS gene set,
however, did not show apparent enrichment (l = 0.78, 0.00%).
However, we did not ﬁnd enrichment for the three mito-
chondrial gene sets tested when we used the MAGMA
pathway analysis tool. One possible explanation is that the
mitochondrial system includes many internal pathways that are
connected with several distinct cellular circuits. Thus, future
studies need to be more reﬁned in terms of deﬁning the
mitochondria-internal pathways to be tested.
We then performed a network-based analysis to explore the
biological signiﬁcance of our ﬁndings. Our in silico in-
vestigations suggested that 14 mitochondrial genes were
functionally connected with risk genes for SCZ and identiﬁed
several biological processes in which mitochondrial genes
were involved in SCZ (respiratory electron transport, respira-
tory electron transport/ATP synthesis, and aldosterone
signaling in epithelial cells).
Of interest, HSPA9 is a chaperone involved in protein quality
control, folding, and degradation, and it has been associated
with Alzheimer’s disease (51). The expression of DNAJC19 has
also been found to be downregulated in the motor cortex and
thalamus of patients with autism (52). The involvement of
respiratory electron transport and ATP synthesis pathways
support impaired OXPHOS functioning in SCZ subjects, which
has already been proposed as part of the etiology of the
disease (11).
The aldosterone signaling pathway is involved in the regu-
lation of mineral metabolism. Interestingly, aldosterone is
thought to disinhibit N-methyl-D-aspartate receptors due to its
role in the excretion of magnesium ions (Mg21), which may
reduce intracerebral Mg21 levels (53). N-methyl-D-aspartate
receptor hypofunction might explain (at least in part) common
clinical manifestations of SCZ including cognitive deﬁcits,
impaired memory and learning, positive-negative symptoms,
and executive dysfunction (54).
NDUFA6 was the mitochondrial gene with the highest
Quack score (0.104). This gene has been found to be down-
regulated in bipolar patients and has a central role in energy
metabolism and mitochondrial function (55). NDUFA6 is also
downregulated in the analysis of CommonMind Consortium
dorsolateral prefrontal cortex expression in SCZ compared
with control subjects. Another gene, DRG2, is a SCZ risk geneBiologicafound to be involved in the regulation of mitochondrial
morphology and function (56).
Furthermore, we examined whether the mitochondrial genes
connect directly with the SCZ genes, which are considered
important for disease etiology or treatment (15). We found that
DNAJC19, HSPA9, and PCCB had high connectivity with the
following SCZ genes: ATP2A2 (calcium signaling), CNTN4
(neuronal network formation and plasticity), and FXR1
(neurodevelopment).
We have also identiﬁed four nucleus-mitochondria crosstalk
genes listed as associated with SCZ in our gene-based study.
These genes are involved with the mitochondrial unfolded
protein response. This pathway is activated under mitochon-
drial stress and induces the expression of protective genes
(chaperones and proteases) to re-establish protein homeo-
stasis within mitochondria. It may also result in the mainte-
nance of mitochondria with heteroplasmic deleterious
mitochondrial DNA variants (57).
In conclusion, our study was able to identify novel nuclear-
encoded mitochondrial and mitochondria-related (nucleus-
mitochondria crosstalk) genes associated with SCZ using a
gene-based approach. We did not obtain signiﬁcant gene-set
ﬁndings, potentially limited by low signal-to-noise ratio, but
we were able to provide supporting evidence for the variants’
association from a GWAS-HD analysis of individual SNPs. Our
in silico analysis of the top ﬁndings suggests that mitochon-
drial pathways should be further explored in SCZ research.
Importantly, our approach can be applied, with relative ease, to
other complex diseases with a hypothesized mitochondrial
component such as bipolar disorder, Alzheimer’s disease,
Parkinson’s disease, and diabetes.ACKNOWLEDGMENTS AND DISCLOSURES
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